CRISPR/Cas9 Gene-editing to Upregulate LDLR for Treatment of Heterozygous Familial Hypercholesterolaemia

Sep

1

Editas Medicine to Participate in Upcoming Investor Conferences

Aug

5

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Aug

4

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.